View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 4, 2018

Merck and Premier to develop solutions for C. diff infection

Merck has extended its preventative and chronic disease care alliance with healthcare provider Premier to devise new solutions to minimise the recurrence of a Clostridium difficile (C. diff) infection.

Merck has extended its preventative and chronic disease care alliance with healthcare provider Premier to devise new solutions to minimise the recurrence of a Clostridium difficile (C. diff) infection.

Under the arrangement, the partners will develop and test a software platform and coordinator combination to offer surveillance, consultation, support and education to patients.

The project will cover volunteer Premier member health systems and aims to improve access to healthcare services, as well as provide awareness on reducing and detecting disease recurrence.

Merck Hospital/Specialty Marketing associate vice-president Raquel Tapia said: “Combining the technical capabilities of Premier and the therapeutic area expertise of Merck has been instrumental in our ability to address these difficult healthcare challenges.

“By testing the solutions in real-world settings and learning from our growing knowledge base, we’re confident that our work together will help patients.”

“By testing the solutions in real-world settings and learning from our growing knowledge base, we’re confident that our work together will help patients.”

Merck and Premier have been partnering since 2016 to create and test interventions to advance wellness and prevention in certain at-risk patient populations.

Premier expects the latest collaboration to help in enhancing follow-up and management of the condition through increased clinician and patient knowledge.

Statistics indicate that C. diff infects approximately 500,000 people in the US, leading to an estimated $4.8bn in excess healthcare costs annually.

Even though the C. diff infection can be treated, one in five patients experiences a recurrence. Moreover, patients taking antibiotics are said to be more prone to this infection during and one month after therapy.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU